BofA Securities analysts upgraded Stryker (NYSE:SYK) from a Neutral rating to a Buy, while also raising the price target from $310.00 to $315.00.
The analysts' rationale for the upgrade centers on several factors, including Stryker's improved outlook on profit margins, a positive product cycle that could boost revenue growth, strong capital visibility through 2024, a favorable orthopedic segment outlook, and the potential for enhanced operating margins, which could lead to a 2% increase in earnings per share.
As a result, the new price target reflects the same 27x multiple for 2024 earnings but with slightly higher expected EPS.
Symbol | Price | %chg |
---|---|---|
043150.KQ | 26400 | 0 |
6849.T | 2279 | 0 |
294090.KQ | 12150 | 0 |
300760.SZ | 267.95 | 0 |
Stryker (NYSE:SYK) shares were trading more than 2% lower intra-day today despite the company posting strong Q1 earnings and raising its 2023 outlook.
Q1 EPS came in at $2.14, better than the Street estimate of $2.01, driven by broad-based growth, especially in Orthopedics. Revenue was $4.8 billion, beating the Street estimate of $4.56 billion.
The company raised its 2023 organic sales growth outlook to 8.50% at the midpoint (range: 8.0–9.0%) and EPS guidance to $10.15 at the midpoint, ahead of the Street’s 7.3% and $10.03, respectively.
Management expects the strong business momentum to continue throughout the rest of the year with a strong order book and a “super cycle” of new products.